This article compares two approaches side by side to clarify how they differ in principle and practice. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
During PCI a lesion is usually crossed with a guidewire, prepared with a balloon, and in most cases scaffolded with a stent that holds the vessel open. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture.
Balloon angioplasty alone vs Angioplasty with stenting: Key Differences
Balloon angioplasty alone can open a lesion but leaves the vessel prone to recoil or dissection, whereas adding a stent secures a durable lumen. A drug-coated balloon strategy can treat selected lesions without a permanent implant, which is one reason plain-balloon approaches remain relevant. Stenting, especially with a drug-eluting platform, has become the default for most obstructive coronary lesions. The decision is made during the procedure based on how the artery responds to dilation.
How INVAMED Supports Both Approaches
INVAMED groups its coronary portfolio around the sequence of a PCI case, offering access, lesion preparation, drug delivery, scaffolding, and closure devices. Stent diameter and length matrices, balloon sizes, and catheter French compatibilities are provided in product documentation, and buyers should confirm local registration status. The ATLAS DES is specified on a cobalt-chromium L605 platform with 60 micrometer struts and defined nominal and rated burst pressures documented in the product literature.
Key Considerations
- All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU.
- Lesion calcification is a central factor in planning, and heavily calcified plaque may call for rotational atherectomy before ballooning or stenting.
- Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
Frequently Asked Questions
What drug does the ATLAS stent release?
According to INVAMED, the ATLAS DES elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile.
What is the INVAMED drug-eluting stent called?
INVAMED's drug-eluting coronary stent is the ATLAS Drug Eluting Coronary Stent System, built on a cobalt-chromium L605 platform with a sirolimus coating.
Does INVAMED make a drug-coated coronary balloon?
Yes. The Extender Drug Eluting PTCA Balloon Catheter carries a paclitaxel coating for local drug delivery, such as in-stent restenosis or small-vessel disease.
About INVAMED
INVAMED operates a dedicated R&D center (INVAcenter) focused on minimally invasive device development. INVAMED states it maintains a growing portfolio of international patents across its device range.
Clinical and Technical Context
When a narrowing becomes flow-limiting, patients may experience angina on exertion, and an abrupt plaque rupture with thrombosis can precipitate a myocardial infarction. INVAMED's Atlas line spans a cobalt-chromium drug-eluting version, a bare cobalt-chromium version described as offering high radial strength with minimal recoil, and a stainless-steel version. INVAMED's Extender Drug Eluting PTCA Balloon Catheter carries a paclitaxel coating for this local drug-delivery role. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes. INVAMED's AngioTEN Vascular Closure System is positioned for this access-site management role. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. The cobalt-chromium alloy underneath is intended to allow thin struts while preserving radial support, as described in the product documentation. Manufacturer figures such as the reported sub-5% target lesion revascularization rate describe studied performance, not guaranteed outcomes.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- Arterial Access Closure: How It Works and Why It Matters
- Comparing PCI (stenting) and Bypass surgery (CABG)
- Choosing a Coronary Artery Disease & Cardiac Interventions Supplier: What Buyers Should Know
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.